Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Subbiah

Showing results (241-250 of 487) with videos related to

Pageof 49
Sort By:
NPJ Precision Oncology|December 2, 2021
Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibitionNiamh Coleman, Vivek Subbiah, Shubham Pant, et al.
Discovery Medicine|March 1, 2015
Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathiesRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine|January 1, 2015
Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine|January 1, 2015
Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Oncotarget|October 30, 2015
Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicineVivek Subbiah, Michael J Wagner, Mary F McGuire, et al.
Discovery Medicine|March 1, 2015
Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
JCO Clinical Cancer Informatics|November 14, 2025
RadOncRAG: A Novel Retrieval-Augmented Generation Framework Improves Large Language Model Benchmark Performance in Radiation OncologyNikhil Gautam Thaker, Navid Redjal, Adam Dicker, et al.
NPJ Precision Oncology|January 29, 2026
A unified framework for pre-screening and screening tools in oncology clinical trialsDenis Horgan, Joe Paulson, Arturo Loaiza-Bonilla, et al.
Diagnosis (Berlin, Germany)|December 17, 2024
Challenges and barriers for the adoption of personalized medicine in Europe: the case of Oncotype DX Breast Recurrence Score<sup>®</sup> testDenis Horgan, Paul Hofman, Patrizio Giacomini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2017
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue SarcomaVivek Subbiah, Christian Meyer, Ralph Zinner, et al.
Pageof 49

Showing results (241-250 of 487) with videos related to

Sort By:
Pageof 49
NPJ Precision Oncology|December 2, 2021
Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibitionNiamh Coleman, Vivek Subbiah, Shubham Pant, et al.
Discovery Medicine|March 1, 2015
Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathiesRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine|January 1, 2015
Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine|January 1, 2015
Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Oncotarget|October 30, 2015
Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicineVivek Subbiah, Michael J Wagner, Mary F McGuire, et al.
Discovery Medicine|March 1, 2015
Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
JCO Clinical Cancer Informatics|November 14, 2025
RadOncRAG: A Novel Retrieval-Augmented Generation Framework Improves Large Language Model Benchmark Performance in Radiation OncologyNikhil Gautam Thaker, Navid Redjal, Adam Dicker, et al.
NPJ Precision Oncology|January 29, 2026
A unified framework for pre-screening and screening tools in oncology clinical trialsDenis Horgan, Joe Paulson, Arturo Loaiza-Bonilla, et al.
Diagnosis (Berlin, Germany)|December 17, 2024
Challenges and barriers for the adoption of personalized medicine in Europe: the case of Oncotype DX Breast Recurrence Score<sup>®</sup> testDenis Horgan, Paul Hofman, Patrizio Giacomini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2017
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue SarcomaVivek Subbiah, Christian Meyer, Ralph Zinner, et al.
Pageof 49